Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study
American Journal of Cardiovascular Drugs,  Clinical Article

Majewski S et al. – This study demonstrated that selective heart rate (HR) reduction with ivabradine is effective in patients with asthma and chronic obstructive pulmonary disease (COPD), with no alteration in respiratory function or symptoms over the duration of the study. Ivabradine offers an interesting alternative, as an HR–lowering agent, in patients with respiratory disease and contraindications to β–blockers.

Methods
  • This was a randomized, single–center, double–blind, placebo–controlled, crossover trial.
  • Enrolment began in May 2009, and the last patient completed the study in January 2011.
  • The study was conducted in an ambulatory setting.
  • A total of 40 patients completed the study (20 asthmatic patients and 20 COPD patients).
  • Inclusion criteria were: documented diagnosis of asthma or COPD according to international guidelines, age 18–75 years, and mean HR on Holter ECG recording of ≥60beats/min.
  • Exclusion criteria included disease exacerbation in a previous month or inability to understand instructions on the study procedures.
  • All patients received ivabradine 7.5mg twice daily for 5 days and placebo twice daily for 5 days in a crossover manner, in one of the two arms of the study, with at least 2 days of washout between treatments.
  • The main outcome measures included the difference in HR between ivabradine and placebo treatment and change in HR in comparison with baseline.
  • Other evaluated outcomes were differences in the peak expiratory flow rate (PEFR), the daily symptom score, rescue medication consumption, and AEs.

Results
  • Ivabradine produced significantly lower mean HR than placebo in both groups of patients: asthma 67.4±8.38 versus 82.85±11.19beats/min (p<0.001) and COPD 69.75±8.9 versus 81.05±9.75beats/min (p<0.001).
  • Similar results were observed for the minimal HR as well as for the maximal noted HR.
  • In comparision with baseline, ivabradine significantly reduced HR in both groups of studied patients (all p<0.05), whereas placebo did not have such an effect.
  • No significant difference, in either the asthma or the COPD group, was found between ivabradine and placebo in morning and evening peak expiratory flow rate, peak expiratory flow diurnal variability, daily symptom scores, and rescue medication usage (all p>0.05).
  • Both treatments were well tolerated.
  • The incidence of AEs was low and generally similar in both periods of treatment, except for visual symptoms during treatment with ivabradine, which was reported by 5% of the patients.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 Precautionary labelling of foods for allergen content: Are we ready for a global framework? Full Text World Allergy Organization Journal, May 8, 2014    Free full text    Review Article

2 A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: Sorafenib for second line renal cell cancer Full Text Cost Effectiveness and Resource Allocation, May 5, 2014    Free full text

3 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

4 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 25, 2014    Review Article    Clinical Article

5 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

6 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

7 Honey as an effective antimicrobial treatment for chronic wounds Full Text Chronic Wound Care Management and Research, August 21, 2014    Free full text    Review Article

8 Acetaminophen plus ibuprofen versus opioids for treatment of post-tonsillectomy pain in children International Journal of Pediatric Otorhinolaryngology , August 18, 2014    Clinical Article

9 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

10 New cholesterol guideline: LDL goals take backseat to statins Full Text American Pharmacists Association News, November 15, 2013    Free full text    Clinical Guideline

11 Is the standard dose of amoxicillin-clavulanic acid sufficient? Full Text BMC Pharmacology & Toxicology, August 8, 2014    Free full text    Clinical Article

12 “Worm pill” could ease autoimmune disease symptoms Monash University News, August 11, 2014

13 Efficacy of high-dose versus standard-dose influenza vaccine in older adults New England Journal of Medicine, August 15, 2014    Evidence Based Medicine    Clinical Article

14 Bedtime aspirin may be more beneficial for heart patients Full Text Pharmacy Times, December 2, 2013    Free full text    Clinical Article

15 Eating probiotics regularly may improve your blood pressure American Heart Association News, July 24, 2014

16 Therapeutics Initiative warns of statin side effects The University of British Columbia Health News, May 30, 2014

17 Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications Full Text Journal of Pharmacy and Pharmaceutical Sciences, January 3, 2014    Free full text    Clinical Article

18 Are chromium supplements helpful in lowering blood sugar levels? Full Text EurekAlert!, April 10, 2014    Free full text

19 Statin use and mortality among blacks and whites in the Southeastern US Full Text Clinical Epidemiology, August 11, 2014    Free full text    Clinical Article

20 First drug candidate from NIH program acquired by biopharmaceutical company Full Text NIH News, July 10, 2014    Free full text

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close